# Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma

> **NCT03782064** · PHASE2 · TERMINATED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 5 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Nivolumab
- **BIOLOGICAL:** DC/myeloma fusions/GM-CSF

## Key facts

- **NCT ID:** NCT03782064
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-22
- **Primary completion:** 2021-01-31
- **Final completion:** 2021-01-31
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Funding
- **Last updated:** 2023-06-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03782064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03782064, "Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03782064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*